Dr. Bradley J Monk MD
OB-GYN (Obstetrician-Gynecologist) | Gynecologic Oncology500 W Thomas Rd Suite 600 Phoenix AZ, 85013
Dr. Bradley Monk is an obstetrician-gynecologist practicing in Phoenix, AZ. Dr. Monk specializes in women's health, particularly the female reproductive system, pregnancy and childbirth. As an obstetrician-gynecologist, or OB-GYN, Dr. Monk can treat a number of health issues related to the vagina, uterus, ovaries, fallopian tubes and breasts. Dr Monk can also treat women during pregnancy, labor, childbirth and the postpartum period. In this specialty, doctors focus on reproductive care from puberty through adulthood.
Education and Training
Univ of Az Coll of Med, Tucson Az 1988
Obstetrics and GynecologyAmerican Board of Obstetrics and GynecologyABOG
- Phase II trial of vinorelbine in recurrent and progressive epithelial ovarian cancer.
- Protein kinase C isoform expression and activity alter paclitaxel resistance in vitro.
- Interstitial brachytherapy in the treatment of advanced and recurrent vulvar cancer.
- Does human papillomavirus have a role in cancers of the uterine corpus?
- Development and assessment of a general theory of cervical carcinogenesis utilizing a severe combined immunodeficiency murine-human xenograft model.
- Pathologic variables and adjuvant therapy as predictors of recurrence and survival for patients with surgically evaluated carcinosarcoma of the uterus.
- Analysis of gene expression profiles in normal and neoplastic ovarian tissue samples identifies candidate molecular markers of epithelial ovarian cancer.
- Primary invasive carcinoma of the vagina: treatment with interstitial brachytherapy.
- Vaginal hysterectomy as primary treatment of endometrial cancer in medically
- Prevention of cervical cancer with vaccines.
- Reimbursement for surgical procedures in gynecologic oncology.
- Fertility sparing treatment for in situ and early invasive adenocarcinoma of the cervix.
- Bowel resection at the time of primary cytoreduction for epithelial ovarian cancer.
- Primary invasive vaginal cancer in the setting of the Mayer-Rokitansky-Kuster-Hauser syndrome.
- Photodynamic therapy of high-grade cervical intraepithelial neoplasia with 5-aminolevulinic acid.
- Laparoscopic photodynamic diagnosis of ovarian cancer using 5-aminolevulinic acid in a rat model.
- Development of an in vitro chemo-radiation response assay for cervical carcinoma.
- New developments in the treatment of invasive cervical cancer.
- Prognostic factors in neuroendocrine small cell cervical carcinoma: a multivariate analysis.
- HPV infection and number of lifetime sexual partners are strong predictors for 'natural' regression of CIN 2 and 3.
- Early stage cervical cancers containing human papillomavirus type 18 DNA have more nodal metastasis and deeper stromal invasion.
- Human papillomavirus infections: truth or consequences.
- Natural history of the minimally abnormal Papanicolaou smear.
- Radical hysterectomy followed by tailored postoperative therapy in the treatment of stage IB2 cervical cancer: feasibility and indications for adjuvant therapy.
- Cisplatin and irinotecan in squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group.
- Phase II study of cisplatin and vinorelbine in squamous cell carcinoma of the cervix: a gynecologic oncology group study.
- Evaluation of tamoxifen in persistent or recurrent nonsquamous cell carcinoma of the cervix: a Gynecologic Oncology Group study.
- Conservative clitoral preservation surgery in the treatment of vulvar squamous cell carcinoma.
- Cervical cancer screening.
- Evaluation of vinorelbine in persistent or recurrent nonsquamous carcinoma of the cervix: a Gynecologic Oncology Group Study.
- Quality of life outcomes from a randomized phase III trial of cisplatin with or
- Conservation of in vitro drug resistance patterns in epithelial ovarian carcinoma.
- Vaccines against human papillomavirus and cervical cancer: promises and challenges.
- Gene expression profiling of in vitro radiation resistance in cervical carcinoma: a feasibility study.
- The Gore-Tex Surgical Membrane: effectiveness as a barrier to inhibit postradical pelvic surgery adhesions in a porcine model.
- Gynecologic oncology group trials of chemotherapy for metastatic and recurrent cervical cancer.
- Randomized comparison of weekly cisplatin or protracted venous infusion of fluorouracil in combination with pelvic radiation in advanced cervix cancer: a gynecologic oncology group study.
- What is the role of conservative primary surgical management of epithelial ovarian cancer: the United States experience and debate.
- Invasive cervical cancer complicating intrauterine pregnancy: treatment with radical hysterectomy.
- Pretreatment CA-125 and risk of relapse in advanced ovarian cancer.
- Human immunodeficiency virus testing in patients with invasive cervical carcinoma: a prospective trial of the gynecologic oncology group.
- Chemotherapy in the management of cervical carcinoma.
- Activity of trabectedin (ET-743, Yondelis) in metastatic uterine leiomyosarcoma.
- Association between cigarette smoking and prognosis in locally advanced cervical carcinoma treated with chemoradiation: a Gynecologic Oncology Group study.
- Will widespread human papillomavirus prophylactic vaccination change sexual practices of adolescent and young adult women in America?
- Influence of serum and tissue micronutrient levels on the regression of untreated cervical intraepithelial neoplasia 2 and 3.
- Recent advances in human papillomavirus vaccines.
- Topotecan in the management of cervical cancer.
- Phase III trial of ifosfamide with or without paclitaxel in advanced uterine carcinosarcoma: a Gynecologic Oncology Group Study.
- Human papillomavirus vaccine: a new chance to prevent cervical cancer.
- What is the risk of bowel perforation associated with bevacizumab therapy in ovarian cancer?
- Bevacizumab demonstrates activity in advanced refractory fallopian tube carcinoma.
- An early signal of CA-125 progression for ovarian cancer patients receiving maintenance treatment after complete clinical response to primary therapy.
- The evolution of cost-effective screening and prevention of cervical carcinoma: implications of the 2006 consensus guidelines and human papillomavirus vaccination.
- Cost-effectiveness of adding human papilloma virus testing to a managed care cervical cancer screening program.
- Bevacizumab in the treatment of ovarian cancer.
- Wnt signaling in ovarian tumorigenesis.
- Reducing the burden of glandular carcinomas of the uterine cervix.
- Stress, immunity, and cervical cancer: biobehavioral outcomes of a randomized clinical trial [corrected].
- The new era of cervical cancer prevention: HPV vaccination.
- The impact of cervical cancer on quality of life: a personal account.
- Initial lessons learned in HPV vaccination.
- Age considerations when vaccinating against HPV.
- A clinical pathway for postoperative management and early patient discharge: does it work in gynecologic oncology?
- Cervical neoplasia in pregnancy. Part 2: current treatment of invasive disease.
- The pediatrician's role in preventing cervical cancer.
- A feasibility study of topotecan with standard-dose cisplatin and concurrent
- The role of antioxidants and vitamin A in ovarian cancer: results from the Women's Health Initiative.
- Markers of angiogenesis in high-risk, early-stage cervical cancer: A Gynecologic Oncology Group study.
- Recent achievements and future developments in advanced and recurrent cervical cancer: trials of the Gynecologic Oncology Group.
- What is the standard therapy for bulky stage IB cervical cancer?
- Impact on survival of 12 versus 3 monthly cycles of paclitaxel (175 mg/m2) administered to patients with advanced ovarian cancer who attained a complete response to primary platinum-paclitaxel: follow-up of a Southwest Oncology Group and Gynecologic
- Cervical cancer therapy: current, future and anti-angiogensis targeted treatment.
- Systemic therapy for recurrent endometrial cancer: a review of North American trials.
- Beyond platinum for metastatic and recurrent carcinoma of the cervix.
- Prognostic factors for response to cisplatin-based chemotherapy in advanced cervical carcinoma: a Gynecologic Oncology Group Study.
- Prognostic relevance of carbonic anhydrase-IX in high-risk, early-stage cervical cancer: a Gynecologic Oncology Group study.
- Changing the paradigm in the treatment of platinum-sensitive recurrent ovarian cancer: from platinum doublets to nonplatinum doublets and adding antiangiogenesis compounds.
- Bevacizumab toxicities and their management in ovarian cancer.
- The rationale for the use of non-platinum chemotherapy doublets for metastatic and recurrent cervical carcinoma.
- High-throughput profiling of the humoral immune responses against thirteen human papillomavirus types by proteome microarrays.
- Phase II, open-label study of pazopanib or lapatinib monotherapy compared with
- Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer: outcomes in the partially platinum-sensitive (platinum-free interval 6-12 months) subpopulation of OVA-301 phase III randomized trial.
- Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer delays third-line chemotherapy and prolongs the platinum-free interval.
- American Society of Clinical Oncology 2010 Annual Meeting update: summary of selected gynecologic cancer abstracts.
- Assessment and significance of quality of life in women with gynecologic cancer.
- Prospective evaluation of an in vitro radiation resistance assay in locally advanced cancer of the uterine cervix: a Southwest Oncology Group Study.
- Ovarian cancer: relevant therapy, not timing, is paramount.
- An open-label, single-arm Phase II study of intravenous weekly (Days 1 and 8) topotecan in combination with carboplatin (Day 1) every 21 days as second-line therapy in patients with platinum-sensitive relapsed ovarian cancer.
- Biologics in cervical cancer therapy.
- A randomized phase III trial of IV carboplatin and paclitaxel × 3 courses followed by observation versus weekly maintenance low-dose paclitaxel in patients with early-stage ovarian carcinoma: a Gynecologic Oncology Group Study.
- Correlation between CA-125 serum level and response by RECIST in a phase III recurrent ovarian cancer study.
- Circulating tumor cells predict progression free survival and overall survival in patients with relapsed/recurrent advanced ovarian cancer.
- Differentiating squamous cell carcinoma of the cervix and epithelioid trophoblastic tumor.
- American Society of Clinical Oncology 2011 Annual Meeting update: summary of selected gynecologic cancer abstracts.
- An economic analysis of dose dense weekly paclitaxel plus carboplatin versus every-3-week paclitaxel plus carboplatin in the treatment of advanced ovarian cancer.
- Survival data from a phase II, open-label study of pazopanib or lapatinib monotherapy in patients with advanced and recurrent cervical cancer.
- Predictive value of serum CA-125 levels in patients with persistent or recurrent
- Quality of life and survival in advanced cervical cancer: a Gynecologic Oncology Group study.
- Trabectedin as a new chemotherapy option in the treatment of relapsed platinum sensitive ovarian cancer.
- American Society of Clinical Oncology 2012 annual meeting update: summary of selected gynecologic cancer abstracts.
- Patient-reported outcomes in relapsed ovarian cancer: results from a randomized Phase III study of trabectedin with pegylated liposomal doxorubicin (PLD) versus PLD alone.
- Quality-of-life results used to endorse changes in standard of care for recurrent platinum-sensitive ovarian cancer.
- Treatment of metastatic cervical cancer: future directions involving targeted agents.
- Comparison of methods to estimate health state utilities for ovarian cancer using quality of life data: a Gynecologic Oncology Group study.
- Incidence and management of edema associated with trebananib (AMG 386).
- Nibrin is a marker of clinical outcome in patients with advanced serous ovarian cancer treated in the phase III OVA-301 trial.
- Integrating bevacizumab into the management of epithelial ovarian cancer: the controversy of front-line versus recurrent disease.
- Phase III randomized trial of weekly cisplatin and irradiation versus cisplatin and tirapazamine and irradiation in stages IB2, IIA, IIB, IIIB, and IVA cervical carcinoma limited to the pelvis: a Gynecologic Oncology Group study.
- Simultaneous characterization of somatic events and HPV-18 integration in a metastatic cervical carcinoma patient using DNA and RNA sequencing.
- Improved survival with bevacizumab in advanced cervical cancer.
- Chemotherapy-induced neutropenia as a biomarker of survival in advanced ovarian carcinoma: an exploratory study of the gynecologic oncology group.
- Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial.
- The American Society of Clinical Oncology 50th Annual Meeting 2014: an overview and summary of selected abstracts.
- New strategies in advanced cervical cancer: from angiogenesis blockade to immunotherapy.
- SGO guidance document for clinical trial designs in ovarian cancer: a changing paradigm.
- Factors associated with poor quality of life among cervical cancer survivors: implications for clinical care and clinical trials.
- Incorporation of pazopanib in maintenance therapy of ovarian cancer.
- Factors associated with grade 3 or 4 treatment-related toxicity in women with advanced or recurrent cervical cancer: an exploratory analysis of NRG Oncology/Gynecologic Oncology Group trials 179 and 204.
- In vitro chemoresponse in metachronous pairs of ovarian cancers.
- Neurotoxicity in ovarian cancer patients on Gynecologic Oncology Group (GOG) protocol 218: characteristics associated with toxicity and the effect of substitution with docetaxel: an NRG Oncology/Gynecologic Oncology Group study.
- Hereditary predisposition to ovarian cancer, looking beyond BRCA1/BRCA2.
- Development of a platform for systemic antiangiogenesis therapy for advanced cervical cancer.
- Long-term survival advantage and prognostic factors associated with intraperitoneal chemotherapy treatment in advanced ovarian cancer: a gynecologic oncology group study.
- The American Society of Clinical Oncology 51st Annual Meeting 2015: An overview and summary of selected abstracts.
- Development of a technique to detect the activated form of the progesterone receptor and correlation with clinical and histopathological characteristics of endometrioid adenocarcinoma of the uterine corpus.
- State of the science: Emerging therapeutic strategies for targeting angiogenesis in ovarian cancer.
- Development of Olaparib for BRCA-Deficient Recurrent Epithelial Ovarian Cancer.
- Disparities in Vulvar Cancer Reported by the National Cancer Database: Influence of Sociodemographic Factors.
- Expression Patterns of the Wnt Pathway Inhibitors Dickkopf3 and Secreted Frizzled-Related Proteins 1 and 4 in Endometrial Endometrioid Adenocarcinoma: An NRG Oncology/Gynecologic Oncology Group Study.
- Early initiation of chemotherapy following complete resection of advanced ovarian cancer associated with improved survival: NRG Oncology/Gynecologic Oncology Group study.
- Reply to F.M. Muggia.
- Biosimilars: Extrapolating the evidence. A roundtable discussion.
- Weekly vs. Every-3-Week Paclitaxel and Carboplatin for Ovarian Cancer.
- Health-related quality of life in women with recurrent ovarian cancer receiving paclitaxel plus trebananib or placebo (TRINOVA-1).
- Moving beyond the platinum sensitive/resistant paradigm for patients with recurrent ovarian cancer.
- Gynecologic Oncology Research and Practice: a new journal to meet the needs of a growing field.
- In vitro chemoresponse in metachronous pairs of gyneclologic cancers.
- Safety and efficacy of salvage nano-particle albumin bound paclitaxel in recurrent cervical cancer: a feasibility study.
- Patient Counseling and Management of Symptoms During Olaparib Therapy for Recurrent Ovarian Cancer.
- Weekly vs. Every-3-Week Paclitaxel for Ovarian Cancer.
- Saving the best treatment for last?
- Final results of a phase 3 study of trebananib plus weekly paclitaxel in recurrent ovarian cancer (TRINOVA-1): Long-term survival, impact of ascites, and progression-free survival-2.
- Trabectedin as a chemotherapy option for patients with BRCA deficiency.
- The American Society of Clinical Oncology 2016 annual meeting: A review and summary of selected abstracts.
- Carcinogenic human papillomavirus infection.
- ENGOT-ov-6/TRINOVA-2: Randomised, double-blind, phase 3 study of pegylated liposomal doxorubicin plus trebananib or placebo in women with recurrent partially platinum-sensitive or resistant ovarian cancer.
- PARP inhibitor and chemotherapy combination trials for the treatment of advanced malignancies: does a development pathway forward exist?
- The development and use of vascular targeted therapy in ovarian cancer.
- Poly(ADP-ribose) polymerase (PARP) inhibitors as treatment versus maintenance in ovarian carcinoma.
- Mechanistic insights into ADXS11-001 human papillomavirus-associated cancer
- The American Society of Clinical Oncology 2017 Annual Meeting: A review and summary of selected abstracts.
- Therapeutic options for treatment of human papillomavirus-associated cancers - novel immunologic vaccines: ADXS11-001.
- A phase II evaluation of brivanib in the treatment of persistent or recurrent carcinoma of the cervix: An NRG Oncology/Gynecologic Oncology Group study.
- Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240).
- FDA ovarian cancer clinical trial endpoints workshop: A Society of Gynecologic Oncology White Paper.
- Bringing new medicines to women with epithelial ovarian cancer: what is the unmet medical need?
- Optimal treatment for platinum-sensitive recurrent ovarian cancer.
- Ovarian Cancer: Current Treatment and Patient Management.
- Does perioperative blood transfusion affect survival in patients with cervical cancer treated with radical hysterectomy?
- Closure of fascial incisions made at the time of laparoscopy: development of a device.
- Correlation of C-myc and HER-2/neu amplification and expression with histopathologic variables in uterine corpus cancer.
- Small bowel obstruction following radical hysterectomy: risk factors, incidence, and operative findings.
- Adhesions after extensive gynecologic surgery: clinical significance, etiology, and prevention.
- Radical hysterectomy after pelvic irradiation in patients with high risk cervical cancer or uterine sarcoma: morbidity and outcome.
- Open interstitial brachytherapy for the treatment of local-regional recurrences
- Ketorolac tromethamine, a nonsteroidal anti-inflammatory drug: ability to inhibit post-radical pelvic surgery adhesions in a porcine model.
- Effectiveness of two barriers at inhibiting post-radical pelvic surgery adhesions.
- Photodynamic therapy using topically applied dihematoporphyrin ether in the treatment of cervical intraepithelial neoplasia.
- A comparison of intracavitary versus interstitial irradiation in the treatment of cervical cancer.
- Ucla Med Ctr, Obstetrics And Gynecology
- University Of California Los Angeles
Dr. Bradley J Monk MD's Practice location
Phoenix, AZ 85013Get Direction
Orange, CA 92868Get Direction
PHOENIX, AZ 85016Get Direction
Dr. Bradley J Monk MD's reviewsWrite Review
Patient Experience with Dr. Monk
- How Is Vaginitis Diagnosed?
Vaginitis is a common condition experienced by women. Yes, it can be uncomfortable, and you can easily feel uncomfortable even while relaxing because down there it’s not fine. Maybe there is a bit of a smell, itchiness, or discharge that are unusual and you may want to take action for things to go...
- Why Should I Breastfeed My Baby?
Whether to breastfeed or bottle-feed a baby is one of the toughest choices that any expectant mothers and new parents have to make. Although the choice is personal, it is better to know a few pros and cons of each feeding method to help parents make the best choice for their babies.It is highly...
- Preparing for a Mammogram with Fibromyalgia
When the treatment is accompanied by pain, it is always hard to move a step forward and consult a doctor. Here are some good and helpful ways to prepare for a less painful treatment.Being a woman comes with high chances of physical pain, from dysmenorrhea to chest pains that range from mild to...
- 6 Post-Pregnancy Body Changes You Should Know About
Low sex driveSleepless nights and a drop in the levels of estrogen all combine together to give a low drive for sex after pregnancy. “Some of them may take up to a year to get back their normal mood and sex drive," says Hope Ricciotti, MD, an associate professor of obstetrics and gynecology at...
- The Benefits and Risks of an IUD
What is an intrauterine device or IUD?An intrauterine device or IUD is a tiny, T-shaped birth control device. It is basically a plastic device, which is wrapped in copper. It also contains certain hormones. An IUD is inserted into the uterus by a doctor. There is a plastic string tied to the end of...
- HIV: Will My Child Get It If I’m Pregnant?
The initials 'HIV' stand for Human Immunodeficiency Virus. As the name suggest, it is a viral attack that completely weakens the defense systems of a human being leaving them open to invasion from bacteria and other disease causing micro-organisms.Once infected, the virus finds its way into the...
- Eugenia G. Politis 85032
- Gino Tutera5410 N Scottsdale Rd Paradise Valley Arizona 85253
- Mandeep K. Kingra2545 West Frys Road Chandler Arizona 85224
- Dr. Debra Wickman MD485 S Dobson Rd Chandler AZ 85224
- Dr. Ernesto M. Gomez M.D.1039 North Country Club Drive Mesa Arizona 85201
- Ms. Carolyn Kenia Ross M.D.7580 Fannin Street Houston Texas 77056